COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Texas
This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), is made as of September 29, 2008 by and between Repros Therapeutics Inc., a Delaware corporation, with its principal executive offices located at 2408 Timberloch Place, Suite B-7, The Woodlands, Texas 77380 (the “Company”), and Efficacy Capital, LTD (the “Investor”).
FIRST AMENDMENT TO STANDSTILL AGREEMENTStandstill Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware
This FIRST AMENDMENT TO STANDSTILL AGREEMENT (the “Amendment”), dated as of July , 2008, is by and between REPROS THERAPEUTICS INC., a Delaware corporation (the “Issuer”), and EFFICACY CAPITAL, LTD (“Efficacy”).
Initial Director’s Grant)Non-Employee Director’s Stock Option Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made as of the 26th day of September 2008, between REPROS THERAPEUTICS INC., a Delaware corporation (the “Company”), and Mark Lappe (“Director”).
SECOND AMENDMENT TO STANDSTILL AGREEMENTStandstill Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware
This SECOND AMENDMENT TO STANDSTILL AGREEMENT (the “Amendment”), dated as of October 2, 2008, is by and between REPROS THERAPEUTICS INC., a Delaware corporation (the “Issuer”), and EFFICACY CAPITAL, LTD (“Efficacy”).
